KEGG   DRUG: AlemtuzumabHelp
Entry
D02802                      Drug                                   

Name
Alemtuzumab (USAN/INN);
Alemtuzumab (genetical recombination) (JAN);
Campath (TN);
Lemtrada (TN)
Product
Remark
Therapeutic category: 4291
ATC code: L04AA34
Product: D02802<JP/US>
Efficacy
Antineoplastic, Anti-CD52 antibody
  Disease
B-cell chronic lymphocytic leukemia [DS:H00005]
Multiple sclerosis [DS:H01490]
Comment
Monoclonal antibody
Target
CD52 [HSA:1043] [KO:K06488]
Interaction
Drug interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AA Selective immunosuppressants
     L04AA34 Alemtuzumab
      D02802  Alemtuzumab (USAN/INN) <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D02802  Alemtuzumab (USAN/INN); Alemtuzumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   CD molecules
    CD52
     D02802  Alemtuzumab (USAN/INN) <JP/US>
Antineoplastics [br08340.html]
 D02802
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D02802
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D02802
BRITE hierarchy
Other DBs
CAS: 216503-57-0
PubChem: 17396960
DrugBank: DB00087
NIKKAJI: J2.415.690G

» Japanese version   » Back

DBGET integrated database retrieval system